Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 357Unspecified Adult Solid Tumor, Protocol Specific 302Advanced Solid Tumor 274Solid Tumor 237Solid Tumors 233Mesothelioma 84Mesothelioma, Malignant 79Solid Tumor, Adult 65Carcinoma, Non-Small-Cell Lung 57Ovarian Neoplasms 38Melanoma 35Lung Neoplasms 29Advanced or Metastatic Solid Tumors 27Neoplasms 26Carcinoma, Renal Cell 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Pancreatic Neoplasms 25Solid Tumours 24Sarcoma 24Colorectal Neoplasms 24Retinoblastoma 22Esophageal Neoplasms 22Advanced Malignant Solid Tumors 22Unspecified Childhood Solid Tumor, Protocol Specific 21Squamous Cell Carcinoma of Head and Neck 20Breast Neoplasms 20Advanced Solid Tumours 20Triple Negative Breast Neoplasms 19Small Cell Lung Carcinoma 19

Interventions

vadimezan 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced or Recurrent Solid Tumors × Other solid neoplasm × Clear all
NCT06541639 2025-03-18

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

Peking University

Phase 1 Recruiting
78 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumors

NCT01285453 2020-12-09

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Novartis

Phase 1 Completed
9 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡